Safety and Antiviral Activity of Albinterferon Alfa-2b Dosed Every Four Weeks in Genotype 2/3 Chronic Hepatitis C Patients

Clinical Gastroenterology and Hepatology

Volumn 6, Issue 6, 2008, Pages 701-706

  Bain, Vincent G ^a   Kaita, Kelly D ^b   Marotta, Paul ^c   Yoshida, Eric M ^d   Swain, Mark G ^a   Bailey, Robert J ^e   Patel, Keyur ^f   Cronin, Patrick W ^g   Pulkstenis, Erik ^g   McHutchison, John G ^f   Subramanian, G Mani ^g  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^g GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBINTERFERON ALFA 2B; ALBUMIN ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ABNORMAL LABORATORY RESULT; ADULT; ALOPECIA; ANTIVIRAL ACTIVITY; ARTHRALGIA; ARTICLE; BACKACHE; CHILL; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; FATIGUE; FEMALE; FEVER; GENOTYPE; HEADACHE; HEPATITIS C; HUMAN; INSOMNIA; INSULIN RESISTANCE; MALE; MOOD CHANGE; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRODUCTIVE COUGH; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; TREMOR; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 44749094657     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2008.02.056     Document Type: Article

References (23)

1. World Health Organization. Hepatitis C (fact sheet no164). Updated October 2000. http://www.who.int/mediacentre/factsheets/fs164/en/ Accessed on September 14, 2007
2. Shepard C.W., Finelli L., and Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5 (2005) 558-567
3. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
4. Hadziyannis S.J., Sette Jr. H., Morgan T.R., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C-a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
5. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
6. Mangia A., Santoro R., Minerva N., et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 352 (2005) 2609-2617
7. von Wagner M., Huber M., Berg T., et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129 (2005) 522-527
8. Shiffman M.L., Suter F., Bacon B.R., et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 357 (2007) 124-134
9. Osborn B.L., Olsen H.S., Nardelli B., et al. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 303 (2002) 540-548
10. Liu C., Zhu H., Subramanian G.M., et al. Anti-hepatitis C virus activity of albinterferon alfa-2b in cell culture. Hepatol Res 37 (2007) 941-947
11. Balan V., Nelson D.R., Sulkowski M.S., et al. A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir Ther 11 (2006) 35-45
12. Bain V.G., Kaita K.D., Yoshida E.M., et al. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 44 (2006) 671-678
13. McHutchison J., Zeuzem S., Benhamou Y., et al. Interim antiviral and safety data with albumin interferon alfa-2b combined with ribavirin in a phase 2b study conducted in patients with genotype 1, IFN-naïve, chronic hepatitis C infection. Hepatology 44 Suppl 1 (2006) 1141 abstr
14. Nelson D., Rustgi V., Balan V., et al. Sustained virologic response rates with albumin interferon alfa-2b in combination with ribavirin in non-responders to prior interferon therapy: interim results from a phase 2 study. Hepatology 44 Suppl 1 (2006) 1136 abstr
15. Puri P., and Sanyal A.J. Role of obesity, insulin resistance, and steatosis in hepatitis C virus infection. Clin Liver Dis 10 (2006) 793-819
16. Patel K., Zekry A., and McHutchison J.G. Steatosis and chronic hepatitis C virus infection: mechanisms and significance. Clin Liver Dis 9 (2005) 399-410
17. Lewis G.F., Carpentier A., Adeli K., et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 23 (2002) 201-229
18. Leandro G., Mangia A., Hui J., et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 130 (2006) 1636-1642
19. Conjeevaram H.S., Kleiner D.E., Everhart J.E., et al. Virahep-C Study Arm. race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 45 (2007) 80-87
20. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
21. Pazienza V., Clement S., Pugnale P., et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 45 (2007) 1164-1171
22. Kawaguchi T., Ide T., Taniguchi E., et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 102 (2007) 570-576
23. Waris G., Felmlee D.J., Negro F., et al. Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J Virol 81 (2007) 8122-8130